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Reduction in Post-Botulinum Toxin Flu-like Symptoms After Injection with Incobotulinum Toxin 
Edwin George, MD, PhD and Natalya Shneyder, MD 
Wayne State University School of Medicine, Detroit, MI 
ABSTRACT 
RATIONALE 
RESULTS INTRODUCTION 
METHODS 
CONCLUSIONS 
Incobotulinum toxin is a botulinum toxin A preparation where the active peptide is 
separated from the neurotoxin associated proteins (hemagglutinins and non-
hemagglutinins) through a series of steps yielding the active neurotoxin with molecular 
weight of 150 kDa, without accessory proteins. Since it is thought the neurotoxin 
associated proteins may be responsible for the flu-like symptoms associated with 
botulinum toxin injections, we decided to offer incobotulinum toxin A injections to 
patients who had previously reported any of the flu-like symptoms after botulinum 
toxins. 
OBJECTIVE: To determine if patients reporting flu-like symptoms (FLS) after 
botulinum toxin (BoNT) injections are less susceptible to this reaction after 
incobotulinum toxin. 
BACKGROUND: Approximately 10% of patients injected with BoNT in our clinic 
complain of FLS, primarily malaise, myalgias and rhinorrhea, beginning a few days to 
one week after injection and lasting one week or less. A review by Baizabal-Carvallo et 
al. (Toxicon, 2011, 58:1-7) found rates of FLS between 1.7 and 20% in patients after 
various preparations of botulinum toxin A, and a subsequent study showed increased 
cytokines in patients with FLS (Neurotoxicity Research, 2013, 24:298-306). Besides the 
neurotoxin itself, most BoNT preparations contain associated complexing proteins 
(NAPs), most of which are hemagglutinins. It is thought that NAPs induce the release of 
inflammatory cytokines, which may cause the FLS. Incobotulinum toxin is a botulinum 
toxin A preparation where the active peptide is separated from the NAPs 
(hemagglutinins and non-hemagglutinins) through a series of steps yielding the active 
neurotoxin with molecular weight of 150 kDa, without accessory proteins. 
DESIGN/METHODS: Consecutive patients who reported FLS consistently occurring 
after previous BoNT injections (> two prior treatment sessions, average 21 sessions, 
patients reporting FLS after “most sessions”) were offered further injections with 
incobotulinum toxin at similar doses. 
RESULTS: Six patients were identified as having had FLS and given injections with 
incobotulinum toxin. Three were cervical dystonia patients, and one each with 
blepharospasm, hemi-facial spasm and tics secondary to Tourette’s. All reported a 
satisfactory clinical response similar to their previous injections. One patient had only 
rhinorrhea, the others had malaise and myalgias. None of the patients experienced flu-
like symptoms after incobotulinum toxin injections (16 treatment sessions). 
CONCLUSIONS: Initial results from this open-label, unblinded series suggests patients 
who have consistently experienced FLS after BoNT injections are much less likely to do 
so after injection with incobotulinum toxin. 
Initial results from this open-label, unblinded series suggests patients who have 
consistently experienced flu-like symptoms after injections with other botulinum toxin 
are much less likely to do so after injection with incobotulinum toxin. 
 
Study Supported by: Wayne State University Fund for Medical Research and Education 
Consecutive patients who reported flu-like symptoms consistently occurring after 
previous botulinum toxin injections were offered further injections with incobotulinum 
toxin at similar doses. All patients included had undergone more than two prior 
treatment sessions, and the average was 21 sessions/patient.  Patients reporting any of 
the flu-like symptoms after previous injections were asked about the frequency with 
which the symptoms had occurred. Specific occurrences could not be reliably quantified 
retrospectively in all cases, but the patients included identified one or more flu-like 
symptoms as occurring within one week after “most treatment sessions”, and believed 
they had experienced a consistent pattern of flu-like symptoms after the prior injections.  
Six patients were identified as having had flu-like symptoms and given injections with 
incobotulinum toxin (3 male, 3 female, mean age 59 years, range 26-80 years). Three 
were cervical dystonia patients, and one each with blepharospasm, hemi-facial spasm 
and tics secondary to Tourette’s. All reported a satisfactory clinical response to 
incobotulinum injections similar to their previous injections. One patient had only 
rhinorrhea, the others had malaise and myalgias. None of the patients experienced flu-
like symptoms after incobotulinum toxin injections (16 treatment sessions). 
Clostridium botulinum are anaerobic bacteria that produce botulinum neurotoxins that 
cause botulism by interfering with synaptic transmission at neuromuscular junctions. 
Different clostridium botulinum strains produce seven immunologically distinct 
serotypes of botulinum neurotoxins, but only serotypes A, B, and F have been used for 
therapeutic purposes. Serotype A is the most frequently used. Three forms of botulinum 
toxin A are commercially available in the USA: Botox® (Allergan, Irvine, CA), 
Dysport® (Ipsen Biopharm, Wrexham, UK), and Xeomin® (Merz Pharmaceuticals, 
Frankfurt, Germany). The non-A serotype, botulinum toxin B, is commercially available 
as Myobloc® (Solstice Neurosciences, Inc., South San Francisco, CA, USA). Each 
preparation has a unique pharmacological profiles and set of side effects (Albanese, 
2009). Many adverse effects have been reported with botulinum neurotoxin 
administration, but most of them are related to the mechanism of action of the toxin, 
including muscle weakness, ptosis, and dysphagia. Systemic reactions following 
botulinum neurotoxin administration primarily comprise nausea, fatigue, malaise, rash, 
and flu-like symptoms. Flu-like symptoms refers to a group of symptoms that includes: 
fever, nonproductive cough, sore throat, myalgia, shivering, chills, malaise, anorexia, 
and headache (Cox and Subbarao, 1999). Besides the neurotoxin itself, most botulinum 
neurotoxin preparations contain associated complexing proteins, most of which are 
hemagglutinins. It is thought that these neurotoxin associated proteins induce the release 
of inflammatory cytokines, which may cause the flu-like symptoms.  
Indication for Botulinum 
Toxin Therapy N Botulinum toxin Flu-like Symptoms 
Cervical dystonia 2 Onabotulinum toxin A Myalgias & malaise 
1 Rimabotulinum toxin B Myalgias & malaise 
Blepharospasm 1 Onabotulinum toxin A 
 
Myalgias & malaise 
 
Hemi-facial spasm 1 Onabotulinum toxin A 
 
Rhinorrhea & malaise 
 
Organic tics 1 Onabotulinum toxin A 
 
Myalgias & malaise 
 
DISCUSSION 
This was an open-label, unblinded clinical series with a very small number of patients, 
so the interpretation is limited. None of the patients identified had been on 
abobotuliunum toxin A (Dysport®). The package insert for Xeomin® (incobotulinum 
toxin A) indicates that nasopharyngitis and respiratory tract infection were reported in 
clinical trials at rates greater than for placebo (5% vs. 3%), and although myalgias and 
malaise were not listed as adverse effects seen in clinical trials, myalgia is mentioned as 
occurring in post-marketing reports. Nonetheless, rates of flu-like symptoms reported 
for the other botulinum toxin preparations are higher, similar to our own experience of 
approximately 10% (Toxicon, 2011, 58:1-7).  These differences are of uncertain 
significance, but the cross-over nature of  our clinical experience suggests they are real. 
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